Scotland First Minister Nicola Sturgeon has urged the UK government to provide answers on how much Brexit will cost the country’s National Health Service (NHS).

With Brexit less than six months away, concerns are increasing over a hard or no-deal, where the UK will leave the European Union (EU) without an official agreement.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Scottish government is also working towards reducing the potential damage that Brexit may cause to its health sector.

Sturgeon said: “Far from the £350m extra a week promised to the NHS from Brexit, there is growing evidence of mounting costs. It’s now time the UK Government came clean on the scale of the cost to our health service.

“The Prime Minister failed to guarantee there would be no interruption in medicine supplies after Brexit. This came after UK ministers published a truncated tender, at a cost of tens of millions of pounds, associated with medicines stockpiling.”

“Far from the £350m extra a week promised to the NHS from Brexit, there is growing evidence of mounting costs.”

The First Minister added that improvements to oncology care will also be impacted due to Brexit’s affect on Scottish NHS. Currently, the country is investing more than £100m over five years to enhance the prevention, detection, diagnosis, treatment and aftercare of cancer patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Sturgeon noted: “Cancer Research UK said last month ‘a no-deal Brexit is clearly the worst outcome for cancer patients and research in both the UK and EU27’.

“This is backed up as cancer experts have warned that ending freedom of movement could be catastrophic for research, which risks undermining patient cancer care.”

The government further expressed concerns over loss of millions in research funding, which is likely to impact clinical trials. It is believed that staying in the Customs Union and Single Market would reduce the Brexit damage and ensure access to the required frontline and research staff.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact